# A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment

> **NCT07376720** · NA · NOT_YET_RECRUITING · sponsor: **Donghua Zhang** · enrollment: 28 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells

## Key facts

- **NCT ID:** NCT07376720
- **Lead sponsor:** Donghua Zhang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-15
- **Primary completion:** 2028-10-30
- **Final completion:** 2029-10-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07376720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07376720, "A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07376720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*